Dr. William Hancock, the Bradstreet Chair in Chemistry and Chemical Biology and an expert in protein drugs, has been invited to serve as a consultant as a consultant to the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA).
by Emily Ashbolt, Biomedical Physics, 2017 For the past decade, Northeastern University Chemistry and Chemical Biology professor Penny Beuning has focused her research on cellular responses to DNA damage, specifically a family of DNA polymerases that deal with copying the damaged DNA. Her tireless work in this area of chemistry has earned her the Chemical Research […]
New research from the Center for Drug Discovery at Northeastern presents a series of molecules that can be controllably deactivated, thereby reducing the side effects of potentially valuable drugs.
Chemistry and chemical biology professor John R. Engen uses a novel technique to analyze large, complex biopharmaceutical drugs, which could have major implications for healthcare and its associated costs.
Nearly two-dozen students shared their co-op experiences with their peers at the College of Science Spring Co-op Expo on Friday in the Raytheon Amphitheater.
The secrecy model that dominates drug discovery doesn’t work for neglected tropical diseases. Associate Professor Michael Pollastri hopes to shift that paradigm with a new platform for secure data-sharing.
With time, the amino acid known as asparagine will eventually degrade.
This year marks the 40th anniversary of the founding of Northeastern’s Barnett Institute of Chemical and Biological Analysis.
Northeastern University’s Barnett Institute of Chemical and Biological Analysis formally announced a technology alliance partnership with Thermo Fisher Scientific, a multibillion-dollar analytical instrumentation and product company, based in San Jose, Calif., with corporate offices in Waltham, MA.
Dan Shea focuses his work on BPAs — not the ones associated with plastics, but rather a class of anti-cancer drugs that also has anti-microbial properties.